Honokiol, a constituent of Magnolia species, inhibits adrenergic contraction of human prostate strips and induces stromal cell death

Daniel Herrmann, Andrea Schreiber, Anna Ciotkowska, Frank Strittmatter, Raphaela Waidelich, Christian G. Stief, Christian Gratzke, Martin Hennenberg

Department of Urology, Ludwig-Maximilians University, Munich, Germany

Purpose: Smooth muscle contraction and prostate growth are important targets for medical therapy of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia. Honokiol and Magnolol are lignan constituents of Magnolia species, which are used in traditional Asian medicine. Here, we examined effects of honokiol and magnolol on contraction of human prostate tissue and on growth of stromal cells.

Methods: Prostate tissues were obtained from radical prostatectomy. Contraction of prostate strips was examined in organ bath studies. Effects in stromal cells were assessed in cultured immortalized human prostate stromal cells (WPMY-1). Ki-67 mRNA was assessed by reverse transcription-polymerase chain reaction, and proliferation by a fluorescence 5-ethynyl-2'-deoxyuridine assay.

Results: Honokiol (100μM) reduced noradrenaline-induced contractions, which was significant at 10 to 100μM noradrenaline. Honokiol reduced phenylephrine-induced contractions, which was significant at 3 to 100μM phenylephrine. Honokiol reduced electric field stimulation-induced contractions very slightly. In WPMY-1 cells, honokiol (24 hours) induced cell death. Magnolol (100μM) was without effects on contraction, and cellular viability.

Conclusions: Honokiol inhibits smooth muscle contraction in the human prostate, and induces cell death in cultured stromal cells. Because prostate smooth muscle tone and prostate growth may cause LUTS, it appears possible that honokiol improves voiding symptoms.

Keywords: Magnolia, Honokiol, Prostatic hyperplasia, Lower urinary tract symptoms, Adrenergic alpha-1 receptors

INTRODUCTION

Medical therapies of lower urinary tract symptoms (LUTS) target either smooth muscle contraction in the lower urinary tract, or prostate growth [1]. In fact, exaggerated α1-adrenoceptor-mediated contraction, and enlargement of the prostate may both contribute to bladder outlet obstruction and LUTS in patients with benign prostatic hyperplasia (BPH) [2]. Consequently, options for medical treatment comprise application of α1-blockers to induce prostate smooth muscle relaxation, and 5α-reductase inhibitors to reduce prostate growth and volume [1].

In addition to α1-blockers and 5α-reductase inhibitors, the use of phytotherapeutics is extremely widespread at least in Western Europe and the United States [3,4]. Several preparations containing combined plant extracts are available without prescription, and still represent an important mainstay of LUTS therapy [5]. Their use is widespread; it has been estimated that phytotherapeutics may still reach up to 30% of total expenses for medical LUTS therapy, which amounted to 4.8 billion USD worldwide in 2009 [3,6,7]. Although their effects are controver-
sially discussed, several clinical studies meeting World Health Organization (WHO) criteria demonstrated improvements of LUTS, urinary flow rate, and postvoid residual volume [5].

Honokiol and magnolol are neolignan compounds of different Magnolia species [8]. Bark and flowers from Magnolia obovata and Magnolia officinalis have been used to date in traditional Chinese and Japanese herbal medicine for treatment of gastrointestinal disorders, anxiety, and allergic disease [8]. Following isolation and identification of honokiol and magnolol from magnolia extracts, their antitumor activity has been recognized and examined in experimental models [8]. Recent studies suggested that they may induce smooth muscle relaxation in the cardiovascular system, airways, and gastrointestinal tract [9-16]. However, their actions in the lower urinary tract are unknown to date. Here, we investigated the effects of honokiol and magnolol on contraction of human prostate tissue.

MATERIALS AND METHODS

1. Human prostate tissue

Human prostate tissues were obtained from April 2013 to September 2013 from patients undergoing radical prostatectomy (n = 38) for prostate cancer, but without previous transurethral resection of the prostate (TURP). The research was carried out in accordance with the Declaration of Helsinki of the World Medical Association, and has been approved by the ethics committee of the Ludwig-Maximilians University, Munich, Germany. Approval did not allow acquisition or storage of any patients’ data, so that all samples were treated anonymously. Consequently, data analysis with relation to patients’ characteristics (e.g., age) was not possible, what may be viewed as a limitation of the study. Tissues in our study were exclusively taken from the periurethral zone. Most prostate tumors are located to the peripheral zone. Consequently, the extent of malignant areas (if any) in our samples may be neglected. Tissue samples did not exhibit macroscopical signs of neoplasia, cancer, or inflammation. Samples were immediately taken after prostatectomy and subsequent macroscopical pathological examination. Organ bath studies were performed immediately after sampling.

2. Tension measurements

Prostate strips (6 mm x 3 mm x 3 mm) were mounted in 10 mL aerated (95% O₂ and 5% CO₂) tissue baths (Föhr Medical Instruments, Seeheim, Germany), containing Krebs-Henseleit solution (37°C, pH 7.4). Preparations were stretched to 0.5 g and left to equilibrate for 45 minutes. In the initial phase of the equilibration period, spontaneous decreases in tone are usually observed. Therefore, tension was adjusted three times during the equilibration period, until a stable resting tone (0.5 g) was attained. After the equilibration period, maximum contraction induced by 80mM KCl (Krebs-Henseleit solution where NaCl was exchanged by KCl) was assessed. Subsequently, chambers were washed three times with Krebs-Henseleit solution for a total of 30 minutes. Cumulative concentration response curves for noradrenaline or phenylephrine (both from Sigma-Aldrich, Munich, Germany) were created after addition of 100µM honokiol, 100µM magnolol (both from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), or an equivalent volume of solvent (dimethylsulfoxide, DMSO). Frequency response curves induced by electric field stimulation (EFS) were created before and after addition of inhibitors or solvent (DMSO for honokiol, water for tamsulosin, and DMSO for the combination of both). Inhibitors or DMSO were applied 45 minutes before concentration or frequency response curves.

3. Cell culture

WPMY-1 cells are an immortalized cell line obtained from nonmalignant human prostate stroma. Cells were obtained from American Type Culture Collection (Manassas, VA, USA), and kept in Rosewell Park Memorial Institute 1640 (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin at 37°C with 5% CO₂. Before stimulation with honokiol (100µM, 24 hours) or magnolol (100µM, 24 hours), the medium was changed to a FCS-free medium. At the end of the experiment, cells were microscoped and pictures were taken using the AxioCam (Zeiss, Oberkochen, Germany).

4. Determination of mRNA expression by real-time polymerase chain reaction

Total RNA was isolated from WPMY-1 cells using the RNeasy mini Kit (Qiagen, Hilden, Germany). After reverse transcription with AMV reverse transcriptase (Promega, Fitchburg, WI, USA), real-time reverse transcription-polymerase chain reaction was performed to assess Ki-67 and β-actin expression with QuantiTect Primer Assays (Qiagen) using a LightCycler Instrument (Roche Diagnostics, Rotkreuz, Switzerland).

5. Cell proliferation assay

WPMY-1 cells were plated with a density of 50,000/well on a 16-well chambered coverslip (Thermo Scientific, Waltham, MA, USA). After 24 hours, cells were treated with honokiol (100µM) or magnolol (100µM) in FCS-free medium. After further 24 hours, the medium was changed to a 10mM 5-ethyl-
nyl-2'-deoxyuridine (EdU) solution in FCS-free medium containing honokiol or magnolol. After 20 hours, cells were fixed with 3.7% formaldehyde. EdU incorporation was determined using the “EdU-Click 555” cell proliferation assay (Baseclick, Tutzing, Germany) according to the manufacturer’s instructions. In this assay, incorporation of EdU into DNA is assessed by detection with fluorescing 5-carboxytetramethylrhodamine. Counterstaining of all nuclei was performed with 4',6-diamidino-2-phenylindole. Cells were analyzed by fluorescence microscopy (excitation, 546 nm; emission, 479 nm).

6. Drugs and solutions
Honokiol (2-(4-hydroxy-3-prop-2-enyl-phenyl)-4-prop-2-enyl-phenol) and magnolol (4-Allyl-2-(5-allyl-2-hydroxy-phenyl)phenol) are biphenyl lignans, isolated from Magnolia species extracts. Stock solutions (10mM) were prepared with DMSO, and kept at ~20°C until use. Phenylephrine (R)-3-[1-hydroxy-2-(methylamino)ethyl]phenol) is an agonist of the α1-adrenoceptor. Aqueous stock solutions of phenylephrine and noradrenaline (10mM) were freshly prepared before each experiment.

7. Statistical analysis
Data are presented as mean ± standard error of the mean (SEM) with the indicated number of experiments. Two-tailed Student t-test was used for paired or unpaired observations. Values of P<0.05 were considered statistically significant. Concentrations producing the half-maximal responses (EC50 values) for contractile agonists were calculated using GraphPad Prism ver. 6 (GraphPad Software Inc., La Jolla, CA, USA).

RESULTS

1. Adrenergic contraction
Noradrenaline and the α1-adrenergic agonist phenylephrine induced concentration-dependent contractions of hu-
man prostate strips (Fig. 1). These were reduced by honokiol (100µM). Significant inhibition of noradrenaline-induced contraction by honokiol was observed at 10µM (P = 0.016 for honokiol vs. DMSO), 30µM (P = 0.034), and 100µM (P = 0.035) noradrenaline (Fig. 1A). Significant inhibition of phenylephrine-induced contraction by honokiol was observed at 3µM (P = 0.013), 10µM (P = 0.0049), 30µM (P = 0.0028), and 100µM (P = 0.015) phenylephrine (Fig. 1A). In addition to inhibition of force generation, honokiol significantly increased the EC_{50} values for noradrenaline (P = 0.022 for honokiol vs. DMSO) and phenylephrine (P = 0.025) (Table 1).

In contrast, application of magnolol (100µM) caused only slight inhibition of noradrenaline- and phenylephrine-induced contractions, without being significant (Fig. 1B). EC_{50} values for noradrenaline or phenylephrine was not changed by magnolol (Table 1).

2. EFS-induced contraction
EFS induced frequency-dependent contractions of human prostate strips (Fig. 2). Contractions were virtually identical before and after application of DMSO (Fig. 2). In contrast, contractions induced by 8, 16, and 32 were slightly reduced after application of honokiol, without being significant (Fig. 2).

3. Effects of honokiol on WPMY-1 cells
Application of honokiol (100µM) for 24 hours induced death of cultured WPMY-1 cells (Fig. 3). Microscopic examination revealed that cells were completely destroyed by treatment with honokiol.

4. Effects of magnolol on WPMY-1 cells
Application of magnolol (100µM) for 24 hours was without effect on cell cycle of WPMY-1 cells. In a fluorescent EdU assay, 53% of cells showed proliferation after application of magnolol, while 57% showed proliferation in control samples (Fig. 4). Magnolol did not change the mRNA expression of the proliferation marker, Ki-67 (Fig. 4).

DISCUSSION
Our findings demonstrate that honokiol may interfere with contraction and cell cycle in the human prostate. Induction of smooth muscle relaxation by α₁-adrenoceptor blockers, and inhibition of prostate growth by 5α-reductase inhibitors are important strategies for medical LUTS therapy [17]. However, a single substance targeting prostate contraction and growth at once has not been approved to date. Currently, combination therapies including α₁-blockers and 5α-reductase inhibi-

[Table 1. EC_{50} values for noradrenaline- and phenylephrine-induced contractions of human prostate strips, after application of honokiol, magnolol, or solvent (DMSO)]

|                | Honokiol | DMSO     |
|----------------|----------|----------|
| noradrenaline  | n=10     | n=8      |
| LogEC_{50}     | –5.205 ± 0.049 | –5.159 ± 0.099 |
| phenylephrine  | n=7      | n=5      |
| LogEC_{50}     | –4.926 ± 0.097  | –4.622 ± 0.191  |

Values are presented as mean ± standard error of the mean. DMSO, dimethylsulfoxide. *P < 0.03 vs. corresponding DMSO control.
Magnolol inhibits smooth muscle contraction by critically determining smooth muscle tone [2]. A minor effect of honokiol was observed at EFS-induced contractions with high frequencies. Inhibition of smooth muscle contraction in human prostate strips. Inhibition of smooth muscle contraction by honokiol has been previously reported from the guinea pig ileum, porcine trachea, rat uterus, and from rat aortic rings [9-12]. To the best of our knowledge, our study using human prostate tissue is the first showing inhibition of smooth muscle contraction by honokiol in a smooth muscle preparation of human origin.

In WPMY-1 cells, a line of stromal cells obtained from a nonmalignant human prostate, application of honokiol induced cell death. This is in line with previous findings, where honokiol was studied in prostate cancer or smooth muscle cells [18-22]. Thus, honokiol induced apoptosis or cell cycle arrest in different lines of prostate cancer cells [19,20,22]. Similarly, it induced apoptosis and cell cycle arrest in cultured vascular smooth muscle cells [18,21]. Proliferation of stromal cells is critical for prostate growth and enlargement in BPH [23]. Together, this suggests that in vivo application of honokiol may reduce growth and volume of the hyperplastic prostate.

Contrary to previous findings from other organs and species, magnolol caused no significant inhibition of smooth muscle contractions in human prostate strips. Inhibition of smooth muscle contraction by magnolol was reported from preparations of rat and guinea pig colon, guinea pig ileum, rat aortic rings, rat uterus, and porcine trachea [9-11,13-16]. Similarly, magnolol was without effect on cell cycle of WPMY-1 cells, although it induces apoptosis or cell cycle arrest in cultured prostate cancer and smooth muscle cells [24-28]. Based on studies in the cardiovascular system, it has been previously assumed that effects of magnolol may be cell type- and dosage-specific [29]. Obviously, limitations of magnolol actions are not confined to the cardiovascular system, but also occur in the lower urinary tract, where magnolol acts on smooth muscle contraction in the rat uterus but not in the human prostate [11].

The dual actions of honokiol on contraction and cell cycle in the prostate appears attractive for therapy of LUTS suggestive of benign prostatic obstruction (BPO). Whether honokiol induces improvement of voiding symptoms can only be assessed in vivo. Because prostate-dependent mechanisms can not be studied in wide-spread rodent models, urodynamic effects of honokiol should preferentially examined in clinical proof-of-concept studies. To the best of knowledge, tests in preclinical models did not provide any clues, which may exclude studies with oral uptake of honokiol. In previous studies, which adressed antitumor activity and pharmacokinetics in different animal models, honokiol-containing preparations were mostly applied intravenously, but also orally or even rectally in rats [30]. After rectal application, plasma concen-
trations of honokiol may be up to six times higher compared to oral application, what may be interesting for applications in LUTS therapy [30]. Meanwhile, liposomal formulations of honokiol including polyethylene glycol coated (PEGylated) liposomal honokiol have been and are still developed and tested for in vivo applicatons for anticancer therapies [30-32]. Toxicologic and mutagenic studies in preclinical models suggested that honokiol may be safe and is not genotoxic [30].

For treatment of LUTS, different preparations containing single or mixed plant extracts are available [1,5]. Their high popularity may raise from their easy availability, but also from disappointment of established clinical options. It has been estimated that 36%-45% of patients are not satisfied from treatment with α1-blockers or 5α-reductase inhibitors, raising the need for ablative treatments [17]. Symptoms, assessed as “International Prostate Symptom Score” (IPSS) are improved to 30%–50% by α1-blockers and to 15%–30% by 5α-reductase inhibitors, but to 10%–34% by placebos [1,2,6]. Similarly, maximal flow rate (Qmax) is increased to 15%–40% by α1-blockers, while increases up to 27% were observed in response to placebo [1,2,6]. Finally, side effects may account for discontinuation of medical therapy, with varying rates for α1-blockers or 5α-reductase inhibitors [6]. Together, this raises a high interest for alternative options.

LUTS treatment with plant extracts is still controversially discussed. Several clinical studies meeting international WHO-BPH standards addressed effects of phytotherapy in patients with LUTS suggestive of BPO, with adverse results. Preparations containing plant extracts were often indistinguishable from placebos, with few exceptions [33-37]. Positive findings mostly concerned IPSS, while improvements of Qmax were found rarely [35,36]. Based on these findings, neither a recommendation, nor a clear rejection/dismissal of phytotherapies was given [1,5].

In conclusion, Honokiol inhibits smooth muscle contraction in the human prostate, and induces cell death in cultured stromal cells. Because prostate smooth muscle tone and prostate growth may cause LUTS, it appears possible that honokiol may improve voiding symptoms in patients with BPH.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

We thank Prof. Dr. E. Noessner and her coworkers for support with fluorescence microscopy. This study was supported by grants from the “Deutsche Forschungsgemeinschaft” (DFG) (grants HE 5825/2-1 and GR 3333/2-1), and from the “Friedrich-Baur-Stiftung” (grant 73/13).

REFERENCES

1. Oelke M, Bachmann A, Descaveaud A, Emberton M, Grivas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-40.
2. Hennenberg M, Stief CG, Gratzi C. Prostatic α1-adrenoceptors: New concepts of function, regulation, and intracellular signaling. Neurourol Urodyn 2014;33:1074-85.
3. Lukacs B, Cornu JN, Aout M, Tessier N, Hodee C, Haab F, et al. Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in france: a comprehensive population study. Eur Urol 2013;64:493-501.
4. MacDonald R, Tacklind JW, Rutks I, Wilt TJ. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 2012;109:1756-61.
5. Madersbacher S, Berger I, Ponholzer A, Marszałek M. Plant extracts: sense or nonsense? Curr Opin Urol 2008;18:16-20.
6. Madersbacher S, Marszałek M, Lackner J, Berger P, Schatz G. The long-term outcome of medical therapy for BPH. Eur Urol 2007;51:1522-33.
7. Ventura S, Oliver VI, White CW, Xie JH, Haynes JM, Exintaris B. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol 2011;163:891-907.
8. Lee YJ, Lee YM, Lee CK, Jung JK, Han SB, Hong TJ. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther 2011;130:157-76.
9. Chan SS, Zhao M, Lao L, Fong HH, Che CT. Magnolol and honokiol account for the anti-spasmodic effect of Magnolia officinalis in isolated guinea pig ileum. Planta Med 2008;74:381-4.
10. Ko CH, Chen HH, Lin YR, Chan MH. Inhibition of smooth muscle contraction by magnolol and honokiol in porcine trachea. Planta Med 2003;69:532-6.
11. Lu YC, Chen HH, Ko CH, Lin YR, Chan MH. The mechanism of honokiol-induced and magnolol-induced inhibition on muscle contraction and Ca2+ mobilization in rat uterus. Naunyn Schmiedebergs Arch Pharmacol 2003;368:262-9.
12. Seok YM, Cho HJ, Cha BY, Woo JT, Kim IK. Honokiol attenuates vascular contraction through the inhibition of the RhoA/Rho-kinase signalling pathway in rat aortic rings. J Pharm Pharmacol 2011;63:1244-51.
13. Bian ZX, Zhang GS, Wong KL, Hu XG, Liu L, Yang Z, et al.
Inhibitory effects of magnolol on distal colon of guinea pig in vitro. Biol Pharm Bull 2006;29:790-5.
14. Seok YM, Kim HY, Garmaa O, Cha BY, Woo JT, Kim IK. Effects of magnolol on vascular contraction in rat aortic rings. Clin Exp Pharmacol Physiol 2012;39:28-36.
15. Teng CM, Yu SM, Chen CC, Huang YL, Huang TF. EDRF-release and Ca(2+)-channel blockade by magnolol, an anti-platelet agent isolated from Chinese herb Magnolia officinalis, in rat thoracic aorta. Life Sci 1990;47:1153-61.
16. Zhang M, Zang KH, Luo JL, Leung FP, Huang Y, Lin CY, et al. Magnolol inhibits colonic motility through down-regulation of voltage-sensitive L-type Ca2+ channels of colonic smooth muscle cells in rats. Phytomedicine 2013;20:1272-9.
17. Füllhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Herrmann, et al. Effects of chronic treatment with honokiol in spontaneously hypertensive rats. Phytomedicine 2013;20:1272-9.
18. Fan S, Li X, Lin J, Chen S, Shan J, Qi G. Honokiol inhibits tumor necrosis factor-a-stimulated rat aortic smooth muscle cell proliferation via caspase-3 and mitochondrial-dependent apoptosis. Inflammation 2014;37:17-26.
19. Hahm ER, Arlotti JA, Marynowski SW, Singh SV. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res 2008;14:1248-57.
20. Hahm ER, Singh SV. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther 2007;6:2686-95.
21. Lee B, Kim CH, Moon SK. Honokiol causes the p21WAF1-mediated G1-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells. FEBS Lett 2006;580:5177-84.
22. Zhang GS, Wang RJ, Zhang HN, Zhang GP, Luo MS, Luo JD. Effects of chronic treatment with honokiol in spontaneously hypertensive rats. Biol Pharm Bull 2010;33:427-31.
23. Timms BG, Hofkamp LE. Prostate development and growth in benign prostatic hyperplasia. Differentiation 2011;82:173-83.
24. Lee DH, Szczepanski MJ, Lee YJ. Magnolol induces apoptosis via inhibiting the EGFR/Pi3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem 2009;106:1113-22.
25. Karaki R, Ho OM, Kim DW. Magnolol attenuates neointima formation by inducing cell cycle arrest via inhibition of ERK1/2 and NF-kappaB activation in vascular smooth muscle cells. Biochim Biophys Acta 2013;1830:2619-28.
26. Kim HM, Bae SI, Kim DW, Kim BK, Lee SB, Lee US, et al. Inhibitory role of magnolol on proliferative capacity and matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells. Int Immunopharmacol 2007;7:1083-91.
27. Wu CH, Chen CW, Chen HC, Chang WC, Shu MJ, Hung JS. Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation. J Pharmacol Sci 2005;99:392-9.
28. Chen JH, Wu CC, Hsiao G, Yen MH. Magnolol induces apoptosis in vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 2003;368:127-33.
29. Ho JH, Hong CY. Cardiovascular protection of magnolol: cell-type specificity and dose-related effects. J Biomed Sci 2012;19:70.
30. Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh AP. Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med 2012;12:1244-52.
31. Zheng J, Tang Y, Sun M, Zhao Y, Li Q, Zhou J, et al. Characterization, pharmacokinetics, tissue distribution and antitumor activity of honokiol submicron lipid emulsions in tumor-burdened mice. Pharmazie 2013;68:41-6.
32. Liang Y, Cui G, Wang X, Zhang W, An Q, Lin Z, et al. Pharmacokinetics of honokiol after intravenous guttae in beagle dogs assessed using ultra-performance liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2014 Mar 21 [Epub]. http://dx.doi.org/10.1002/bmc.3179.
33. Coulson S, Rao A, Beck SL, Steels E, Gramotnev H, Vitetta L. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complement Ther Med 2013;21:172-9.
34. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of safflower oil in men with lower urinary tract symptoms. Urology 2001;58:960-4.
35. Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 1995;345:1529-32.
36. Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 2005;5:1-11.
37. Lopatkin N, Sivkov A, Walther C, Schlafke S, Medvedev A, Avdeichuk J, et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms: a placebo-controlled, double-blind, multicenter trial. World J Urol 2005;23:139-46.